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Abstract
AIM: To investigate the efficacy of amitriptyline with 
proton pump inhibitor (PPI) for the treatment of func-
tional chest pain (FCP).
METHODS: This was a randomized, open-label trial 
investigating the addition of low dose amitriptyline (10 
mg at bedtime) to a conventional dose of rabeprazole 
(20 mg/d) (group A, n  = 20) vs  a double-dose of ra-
beprazole (20 mg twice daily) (group B, n  = 20) for 
patients with FCP whose symptoms were refractory to 
PPI. The primary efficacy endpoints were assessed by 
global symptom score assessment and the total num-
ber of individuals with > 50% improvement in their 
symptom score. 
RESULTS: The between-group difference in global 
symptom scores was statistically significant during the 
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last week of treatment (overall mean difference; 3.75 
± 0.31 vs  4.35 ± 0.29, the between-group difference; 
P  < 0.001). Furthermore, 70.6% of patients in group A 
had their symptoms improve by > 50%, whereas only 
26.3% of patients in group B had a similar treatment 
response (70.6% vs  26.3%, P  = 0.008). Specifically, 
patients in group A had a significantly greater improve-
ment in the domains of body pain and general health 
perception than did patients in group B (52.37 ± 17.00 
vs  41.32 ± 12.34, P  = 0.031 and 47.95 ± 18.58 vs  
31.84 ± 16.84, P  = 0.01, respectively).
CONCLUSION: Adding amitriptyline to a PPI was more 
effective than a double-dose of PPI in patients with FCP 
refractory to a conventional dose of PPI.
© 2013 Baishideng. All rights reserved.
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Core tip: Hypersensitivity and psychological problems 
have an important role in the pathogenesis of func-
tional chest pain (FCP). In this regard, the principal 
treatment of FCP has moved towards hypersensitivity 
modulation and antidepressant agents on the basis 
that the underlying mechanisms were increased pain 
perception or visceral hyperalgesia in addition to psy-
chologic causes. This is the first study to report that 
adding low-dose amitriptyline to a conventional dose 
of proton pump inhibitor (PPI) is more effective than a 
double-dose of PPI in patients with FCP resistant to a 
conventional dose of PPI treatment. 
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INTRODUCTION
Noncardiac chest pain (NCCP) is a common condition 
that affects up to one third of  the general population. 
Moreover, the effect of  NCCP on an individual’s quality 
of  life and use of  health care resources is considerable 
because evaluation of  new patients with NCCP may re-
quire a variety of  costly tests. Gastroesophageal reflux 
disease (GERD) is the most common cause of  NCCP 
and is present in up to 60% of  patients with NCCP in 
Western countries[1]. In addition, some patients with 
NCCP are regarded as having functional chest pain (FCP) 
by Rome Ⅲ criteria[2-4].
Despite extensive evidence indicating that the causes 
of  FCP are visceral hypersensitivity and psychiatric pa-
thology[5], the underlying mechanism for FCP has not 
been fully understood. This problem makes the treat-
ment of  FCP quite difficult. Indeed, therapeutic gains 
with a conventional dose of  empirical PPI treatment may 
be obtained in only 9%-39% of  patients with FCP[6,7]. A 
Cochrane review suggests that doubling the PPI dose is 
associated with greater relief  of  symptoms for those with 
NCCP. However, there is no clear PPI dose-response re-
lationship for symptom resolution[8].
Reflecting recent interest, several authors have con-
firmed an important role for hypersensitivity in the 
pathogenesis of  FCP[9,10]. Furthermore, psychological 
evaluation of  patients with FCP has been suggested 
because a significant proportion may meet the criteria 
for panic disorder and depressive symptoms[11,12]. In this 
regard, several studies have assessed the psychological 
treatment of  FCP with tricyclic antidepressants (TCAs), 
selective serotonin reuptake inhibitors, and serotonin-
norepinephine reuptake inhibitors[11,13,14]. Hence, the 
principal treatment of  FCP has moved towards hyper-
sensitivity modulation and antidepressant agents on the 
basis that the underlying mechanisms are increased pain 
perception or visceral hyperalgesia in addition to psycho-
logic causes[15,16]. Consequently, it would be reasonable 
to assume a beneficial effect of  amitriptyline (a TCA) on 
the symptoms of  FCP. As mentioned earlier, these drugs 
could reduce the severity of  psychological manifestations 
which are thought to exacerbate the symptoms of  FCP. 
In addition, amitriptyline has central analgesic actions, in 
addition to local pharmacological actions on the upper 
gut which specifically alter transit and gastric accommo-
dation[16,17]. Although widely used for FCP, the combined 
therapy of  PPI and antidepressant agents is not evidence-
based. The purpose of  this study is to investigate wheth-
er adding low-dose amitriptyline to a conventional dose 
of  PPI is more effective than a double-dose of  PPI in 
patients with FCP resistant to conventional dose of  PPI 
treatment. 
MATERIALS AND METHODS
Patients and study protocol
This was a single-center, prospective, randomized, open-
label trial. Over 8 wk we investigated the addition of  a 
subtherapeutic dose of  amitriptyline to a conventional 
dose of  PPI (group A) vs a double-dose of  PPI (group 
B) for the treatment of  refractory FCP. Consecutive 
patients were recruited for the study who presented to 
the Yonsei University Medical Center with persistent 
unexplained midline chest pain for a minimum of  3 mo, 
and who had a normal upper endoscopy, 24 h impedance 
esophageal pH monitoring, and esophageal manometry. 
Patients were only considered eligible for enrollment if  
they were free from cardiac, musculoskeletal, and pul-
monary diseases, and if  they had < 50% improvement 
of  their global symptom scores after treatment with a 
conventional dose of  PPI (rabeprazole 20 mg/d) for at 
least 1 mo. Patients were excluded if  they had erosive 
esophagitis, Barrett’s esophagus, other GERD-related dis-
orders, or peptic ulcer disease during upper endoscopy. 
In addition, patients were excluded if  they were unable to 
complete 24 h impedance esophageal pH monitoring or 
esophageal manometry, and if  the results of  these tests 
indicated GERD or a definite motility disorder. Finally, 
patients were excluded if  they had a depressive disorder 
[Beck Depression Inventory (BDI) score > 19] or if  they 
refused all procedures of  this study. After signing a writ-
ten informed consent patients were asked to complete a 
baseline Short-Form (SF-36) to generate quality of  life 
(QOL) data, a global symptom score, and a BDI score. 
Enrollees were randomized by an independent investiga-
tor using a computer-generated random number table 
to one of  two groups, whereby those in group A were 
treated with the combination of  amitriptyline (10 mg at 
bedtime) and rabeprazole (20 mg/d), and those in group 
B were treated with a double-dose of  rabeprazole (20 mg 
twice daily).
Efficacy was assessed by patient evaluation of  global 
symptom relief  scores using a daily symptom diary each 
week. At each visit the symptom diary was checked, side 
effects were reported, and compliance was assessed. At 
the end of  the 8 wk study patients were asked to com-
plete a final QOL questionnaire, global symptom and 
BDI scores were generated, and any side effects were 
reported. Primary efficacy endpoints were assessed by 
the subjective global symptom relief  score and the total 
number of  individuals with > 50% improvement in their 
symptom score. Secondary endpoints were related to 
QOL indices and the BDI score. The study described in 
this report was approved by the ethics committee of  Yon-
sei University School of  Medicine, Seoul, South Korea.
Demographics
All subjects completed a demographic questionnaire in-
cluding age, gender, residence area, smoking and alcohol 
history, and body mass index (BMI).
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Symptom assessment
The overall clinical assessment (global symptom score) 
was made using an analogue scale ranging from 0 (no 
symptoms) to 10 (intolerable), carried out immediately 
before treatment[18]. All patients were also questioned 
regarding symptoms possibly related to complications 
of  the treatment. Subsequently, patients were contacted 
every week and re-evaluated for the presence of  clinical 
symptoms. In addition, patients were asked to report to 
the center if  any additional symptoms occurred during 
the study period. In both study groups the treatment 
of  FCP was considered effective if  the global symptom 
score improvement was > 50%[19].
SF-36
Health-related QOL was assessed with the SF-36, which 
contains 36 items that, when scored, yield eight domains. 
This approach was chosen because of  its reliability and 
validity among both diseased and general populations, 
and given its usefulness in comparing the health burden 
of  different conditions and the benefits of  treatment. 
Specifically, the physical functioning domain (10 items) 
assesses limitations of  physical activities, such as walk-
ing and climbing stairs. The physical role (4 items) and 
emotional role (3 items) domains measure problems with 
work or other daily activities as a result of  physical health 
or emotional problems. The body pain domain (2 items) 
assesses limitations due to pain, and the vitality domain 
(4 items) measures energy and tiredness. The social func-
tioning domain (2 items) examines the effect of  physical 
and emotional health on normal social activities, and the 
mental health domain (5 items) assesses happiness, ner-
vousness, and depression. Finally, the general health per-
ception domain (5 items) evaluates personal health and 
the expectation of  changes in health. All domains were 
scored on a scale from 0 to 100, with 100 representing 
the best possible health state.
Depression 
We assessed depression using the BDI instrument. The 
BDI is a self-administered 21-item self-reported scale 
measuring supposed manifestations of  depression. In 
particular, a BDI score between 9 and 18 implies mild-to-
moderate depression, a score between 19 and 30 signifies 
moderate-to-severe depression, and a score > 30 implies 
severe depression. This score was measured before and 
after treatment.
Statistical analysis
On the basis of  a previous meta-analysis with antide-
pressants[20], a two-sided comparison of  the primary 
outcome variable with 17 patients per group, at the end 
of  the treatment period, had the required 90% power 
and 5% type Ⅰ error rate to detect a difference of  40% 
between the groups receiving additional amitriptyline 
and high dose PPI in the number of  patients reporting 
> 50% improvement in symptoms (MedCalc® Version 
12.3; MedCalc Software: Mariarkerke, Belgium). To allow 
for possible dropouts, defined as patients who failed to 
present or failed to follow the medication instructions, 20 
subjects were required for each group.
To account for missing data, analysis of  the primary 
and secondary endpoints was performed according to 
intention to treat (ITT) and per-protocol (PP) analyses. 
Descriptive statistics were provided for the binary and 
continuous variables using the incidence frequency (%) 
and the mean (standard distribution). The χ 2 test or Fish-
er’s exact test was used to compare binary variables, and 
the two sample t test was used to compare continuous 
variables. Between-group differences of  global symptom 
scores over time were analyzed using a linear mixed mod-
el with an unstructured residual covariance matrix. There 
were also two fixed effects that were assessed, including 
a between-subjects treatment effect (group A: amitripty-
line + rabeprazole, group B: double dose of  rabeprazole) 
and a within-subject time effect (time: week 0 to week 
8). A possible group difference across time was analyzed 
by the group and time interaction effect. We also evalu-
ated treatment effects of  the drug on each SF-36 domain 
measured at baseline and during follow-up using a two 
sample t test. Two-sided P values were calculated with sig-
nificance accepted at the 5% level. When necessary, the P 
value was adjusted by Bonferroni correction for multiple 
pair-wise comparisons. We primarily report the outcomes 
evaluated by ITT analysis since there were no differences 
for test results between ITT and PP analyses. All of  the 
statistical analyses were performed using SAS version 9.2 
(SAS Institute Inc., Cary, NC, United States).
RESULTS
Baseline characteristics
Figure 1 shows the progress of  patients throughout the 
study. A total of  73 patients were enrolled in the study, 
all of  whom had persistent unexplained midline chest 
pain for a minimum of  3 mo, a normal upper endos-
copy, 24 h impedance esophageal pH monitoring, and 
esophageal manometry, and an improvement of  their 
global symptom score by < 0% after treatment with a 
conventional dose of  PPI (rabeprazole 20 mg/d) for at 
least 1 mo. The random assignment of  patients into two 
arms resulted in 20 patients in group A designated to 
receive the addition of  amitriptyline 10 mg once daily to 
rabeprazole 20 mg/d, and 20 patients in group B desig-
nated to receive a rabeprazole dose of  20 mg twice daily. 
Overall, 4 patients dropped out of  the study, including 
three patients because of  mild medication side effects (all 
of  whom belonged to group A) and one who was lost to 
follow-up (this patient belonged to group B). Of  the 36 
patients who completed the 8-wk trial 17 were assigned 
to group A and 19 to group B. The ITT population con-
sisted of  40 patients. 
Baseline characteristics for each treatment group in 
the ITT population are summarized in Table 1. The mean 
age of  individuals in group A was 51.1 ± 8.5 years vs 
49.7 ± 9.59 years for those in group B. There was a slight 
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difference between the two groups was not significantly 
different (3.75 ± 0.31 vs 4.35 ± 0.29, P = 0.172). How-
ever, we found that the time effect and time × group 
interaction effect were significant (P < 0.001 and P = 
0.006, respectively). For instance, the global symptom 
scores significantly declined in group A. For group B, 
however, the global symptom scores decreased until 
week 2 and then somewhat increased after week 5 until 
the end of  study follow-up (Table 2). Consequently, the 
between-group difference in global symptom scores was 
statistically significant at the last week (P < 0.001). Figure 
3A shows the response rates in patients with FCP treated 
with amitriptyline and rabeprazole vs the double-dose of  
rabeprazole on the PP analysis. We found that 70.6% of  
amitriptyline and rabeprazole-treated patients showed im-
female predominance in both groups: 55% in group A 
and 60% in group B. Of  those in groups A and B respec-
tively, 15% vs 20% used alcohol and 20% vs 45% smoked 
cigarettes. The mean BMI was 21.56 ± 1.74 for subjects 
in group A and 21.79 ± 2.2 in group B. There were no 
significant differences between group A and group B re-
garding symptom index, acid exposure time, and baseline 
BDI, indicating adequate randomization. Furthermore, 
subjects in both treatment groups of  the ITT population 
showed generally similar values for most laboratory test 
results.
Global symptom score assessment
The global symptom scores over time associated with 
each treatment are shown in Figure 2. The overall mean 
73 patients with persistent unexplained midline chest pain refractory 
to conventional dose of rabeprazole
Exclusion1
Upper endoscopy (n  = 6)
24-h esophageal pH monitoring (n  = 4)
Esophageal manometry (n  = 1)
Excessive BDI score (n  = 1)
Refusal of study or exam (n  = 21)2
40 Eligible subjects with functional chest pain
Baseline symptom assessment
Randomization
Rabeprazole 20 mg and amitriptyline 10 mg (n  = 17) 
Withdrawal (n  = 3)
Rabeprazole 20 mg twice daily (n  = 19)
Withdrawal (n  = 1)
Complete trial (n  = 17) Complete trial (n  = 19)
Total completed trial (n = 36)
Total withdrawal (n  = 4)3
Figure 1  Flow of patients throughout the trial. 1Upper gastrointestinal endoscopy showed erosive gastroesophageal reflux disease (n = 5), and peptic ulcer dis-
ease (n = 1). Pathological acid exposure was found in four patients by ambulatory 24 h esophageal pH monitoring. An esophageal motility disorder was found in one 
patient by esophageal manometric examination. The Beck Depression Index score of one patient exceeded 19 points; 2Sixteen patients refused to take part in this 
study, and five patients refused examination by esophageal manometry or ambulatory 24 h esophageal pH monitoring; 3Out of 4 patients, three in group A withdrew 
because of an amitriptyline-associated adverse event. One patient in group B dropped out of the trial because of loss to follow-up. BDI: Beck Depression Inventory.
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provement by > 50%, and that 29.4% failed to respond, 
given a response of  < 50%. On the contrary, only 26.3% 
of  patients showed a response to a double-dose of  rabe-
prazole. This difference was significant (χ 2 = 7.06, df = 1, 
P = 0.008).
Health-related QOL assessment
Table 3 shows the health-related QOL as assessed by 
the SF-36 before and after treatment. There were no sta-
tistically significant differences between the two patient 
groups at baseline in any of  the eight SF-36 domains. 
Moreover, the treatment effect at the end of  the study 
was not significantly different between most domains of  
the SF-36, except for the body pain and general health 
perception factors. Patients who received amitriptyline 
and rabeprazole treatment had a significantly greater 
improvement in the domains of  body pain and general 
health perception than those who received a double-dose 
of  rabeprazole treatment (P = 0.031 and 0.01, respec-
tively). The majority of  the other domains of  the SF-36 
did not reach statistical significance.
Depression
The overall mean difference of  BDI at baseline and after 
the 8-wk treatment period was not significantly differ-
ent between group A and group B (6.9 ± 2.22 vs 7.35 ± 
1.93, P = 0.498, and 6.71 ± 1.99 vs 7.16 ± 1.89, P = 0.49, 
respectively). There was no significant difference in the 
depression score from baseline to the end of  treatment in 
the double dose of  PPI treatment group (P = 0.3). In the 
group receiving rabeprazole and amitriptyline, this result 
was marginally significant (P = 0.06). The change in value 
of  the BDI scores associated with treatment is shown in 
Figure 3B. 
Tolerability and safety assessment
Three patients withdrew from the study because of  non 
life-threatening adverse events while receiving the combi-
nation of  amitriptyline and rabeprazole (excessive sleep-
ing, dizziness and general weakness).
DISCUSSION
The primary aim of  this study was to determine the ef-
ficacy of  low-dose amitriptyline with a conventional dose 
of  PPI for the treatment of  FCP with refractory symp-
toms to a conventional dose of  PPI. We found favorable 
evidence for the efficacy of  antidepressants in improving 
global symptom scores and health related QOL in pa-
tients with FCP refractory to conventional doses of  PPIs. 
In other words, we found that adding low-dose amitripty-
line to a conventional dose of  PPI resulted in significant-
ly decreased symptoms compared with a double-dose of  
PPI, with minimal side effects. Interestingly, this outcome 
is very similar to the open-label response to antidepres-
sants seen with irritable bowel syndrome[21].
Anti-reflux therapy with PPIs plays an important role 
in the diagnosis and treatment of  patients with NCCP 
because the major cause of  NCCP is GERD, and since 
the management of  NCCP is largely empirical[22,23]. How-
ever, in patients with non GERD-related NCCP (espe-
Table 1  Baseline characteristics of the intention to treat 
population
Variables Group P  value
A (n  = 20) B (n  = 20)
Age (yr) 51.1 ± 8.5 49.7 ± 9.59 0.628
Gender (female) 11 (55) 12 (60) 0.749
Alcohol   3 (15)   4 (20) 0.677
Smoking   4 (20)   9 (45) 0.091
BMI (kg/m2) 21.56 ± 1.74       21.79 ± 2.2 0.716
Region (rural)        9 (52.94)        7 (36.84) 0.332
Symptom index1   5 (25)   5 (25) -
Acid exposure time   0.52% ± 0.68%     0.44% ± 0.8% 0.719
Baseline BDI     6.9 ± 2.22 7.35 ± 1.93 0.498
Data are expressed as absolute numbers (percentage) or mean ± SD. 
1Symptom index indicated number of patients who has score of symptom 
index by > 50% on 24-h esophageal pH monitoring. BMI: Body mass in-
dex; BDI: Beck Depression Inventory. 
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Figure 2  Efficacy of both treatment groups on the global symptom score. 
The global symptom scores over time was associated with each treatment. The 
overall mean difference between the two groups was not significantly different (P 
= 0.172). However, we found that the time effect and time × group interaction 
effect were significant (P < 0.001 and P = 0.006, respectively). Consequently, 
the between-group difference in global symptom scores was statistically signifi-
cant at the last week (P < 0.001).
Table 2  Global symptom scores by follow-up time
Time Group A Group B P  value1
Week 0 5.85 (5.09-6.61) 6.10 (5.34-6.86) 0.642
Week 1 4.90 (4.14-5.66) 5.10 (4.34-5.86) 0.709
Week 2 3.94 (3.08-4.80) 3.90 (3.06-4.74) 0.948
Week 3 3.76 (2.86-4.66) 3.95 (3.10-4.80) 0.755
Week 4 3.82 (2.96-4.68) 3.90 (3.10-4.70) 0.889
Week 5 3.18 (2.38-3.98) 3.80 (3.05-4.55) 0.259
Week 6 3.00 (2.21-3.79) 3.95 (3.21-4.69) 0.084
Week 7 2.89 (2.12-3.65) 4.05 (3.33-4.77) 0.031
Week 8 2.47 (1.68-3.27) 4.37 (3.63-5.11) 0.001
Data are least square means (95%CI). Group A: rabeprazole + amitrip-
tyline group vs Group B: double dose of proton pump inhibitor group. 
1P value < 0.006 is considered statistically significant after adjusting the 
significance level of 0.05 using Bonferroni correction method for multiple 
comparisons. The significant difference between two groups was found at 
week 8 only (P < 0.006).
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cially those refractory to conventional doses of  PPI), 
treatment should be targeted to alternative drugs, such 
as pain modulating agents[24]. Indeed, therapeutic gains 
with PPI treatment have been obtained in only 9%-39% 
of  non GERD-related NCCP patients[6,22,25]. Recent stud-
ies have focused on modulating nociception and visceral 
pain sensation pathways for decreasing chest pain using 
antidepressants[11,26]. For these reasons, it would be rea-
sonable to assume a beneficial effect of  antidepressant 
drugs, such as TCAs, on the symptoms of  FCP. In fact, 
to investigate the efficacy of  antidepressant treatments 
for FCP, one meta-analysis of  seven studies and 319 par-
ticipants indicated that there was strong evidence for an 
association of  antidepressants with a reduction in pain 
and psychological symptoms. However, the drugs as-
sessed in this analysis were varied and included a TCA, 
selective serotonin reuptake inhibitors, and a serotonin-
norepinephine reuptake inhibitor[14]. Therefore, the pos-
sible effect of  amitriptyline for FCP is unclear. Moreover, 
until now there has been no randomized controlled study 
to investigate the effects of  combining TCAs with PPIs 
for the treatment of  FCP refractory to conventional 
therapy. 
The results of  our clinical study suggest that FCP 
may respond favorably to low-dose amitriptyline in com-
bination with a PPI. Eventually the symptomatic overlap 
with functional gastrointestinal disorders, the recognized 
association of  functional dyspepsia with visceral hyper-
sensitivity, and the response of  several other functional 
gut disorders to TCAs may all hold clues to the seeming 
success in our patients. In our study, we used doses of  
amitriptyline far below those necessary for an antidepres-
sant benefit. This likely explains the positive association 
of  amitriptyline for reducing pain in the absence of  a 
benefit for depressive symptoms. The synergistic effects 
of  amitriptyline in combination with a conventional dose 
of  PPI could have an important role in improving QOL 
of  those with FCP. Because the therapeutic effects of  
amitriptyline are usually achieved within 4-6 wk, the dura-
tion of  our trial was considered adequate for evaluating 
the efficacy of  this drug. Our results show that an 8-wk 
treatment regimen with amitriptyline and rabeprazole sig-
nificantly improved the global symptom score given the 
response rate of  70.6%, which was in comparison to the 
Pe
rc
en
ta
ge
 o
f 
pa
tie
nt
s
100
80
60
40
20
0
A Response
No response
rabeprazole + amitriptyline  double dose of rabeprazole
BD
I 
sc
or
e
7.6
7.4
7.2
7.0
6.8
6.6
6.4
6.2
at baseline
after 8 wk
rabeprazole + amitriptyline  double dose of rabeprazole
B
Figure 3  Symptom response rate (A) and Beck Depression Inventory scores (B) after treatment. A: The response rates in patients after treatment with rabepra-
zole + amitriptyline vs double-dose of rabeprazole on the per-protocol analysis are demonstrated. In this analysis, the difference of the response rate between both 
groups was statistically significant; B: The Beck Depression Inventory (BDI) scores after treatment with amitriptyline and rabeprazole vs double-dose of rabeprazole 
are represented. The overall mean difference of BDI scores after 8 wk of treatment was not significantly different between group A and group B (6.71 ± 1.99 vs 7.16 ± 
1.89, respectively; P = 0.49).
Table 3  Treatment effect on the health-related quality of life 
assessed with Short-Form 36
SF-36 score Group P  value
Group A (n  = 20) Group B (n  = 20)
Physical functioning
   Baseline 42.01 ± 13.47 32.83 ± 17.06 0.211
   End of treatment 37.28 ± 12.76        38.42 ± 7.83 0.753
Role -physical
   Baseline 31.51 ± 14.9 29.45 ± 15.51 0.670
   End of treatment   37.88 ± 10.16 39.02 ± 12.49 0.768
Role-emotional
   Baseline 32.01 ± 12.12 38.39 ± 12.68 0.112
   End of treatment 36.99 ± 12.62 30.14 ± 16.95 0.182
Social functioning
   Baseline 37.95 ± 14.06 33.82 ± 13.90 0.356
   End of treatment 36.41 ± 13.03 30.07 ± 12.83 0.151
Body pain
   Baseline 34.94 ± 14.39 30.13 ± 12.09 0.260
   End of treatment 52.37 ± 17.00 41.32 ± 12.34 0.031
General health perceptions
   Baseline 38.63 ± 11.66 31.82 ± 12.94 0.088
   End of treatment 47.95 ± 18.58 31.84 ± 16.84 0.010
Mental health
   Baseline 38.82 ± 14.72 39.20 ± 10.67 0.927
   End of treatment 44.69 ± 10.79 38.88 ± 10.50 0.111
Energy/vitality
   Baseline 38.08 ± 12.50 34.39 ± 12.64 0.360
   End of treatment 42.95 ± 15.32 35.14 ± 10.87 0.084
All results are expressed as mean ± SD. Group A received amitriptyline 
and rabeprazole and group B received double dose of rabeprazole. P 
values are for the comparison of amitriptyline and rabeprazole vs double 
dose of rabeprazole at baseline and end of the treatment. Patients who re-
ceived amitriptyline and rabeprazole treatment had a significantly greater 
improvement in the domains of body pain and general health perception 
than those who received a double dose of rabeprazole treatment (P = 0.031 
and P = 0.01, respectively). The majority of the other domains of the Short-
Form 36 (SF-36) did not reach statistical significance.
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response rate for a double-dose of  rabeprazole of  only 
26.3%. However, analysis of  the SF-36 as a QOL mea-
surement showed satisfactory efficacy in only two do-
mains. This might have been caused by the small sample 
size, which may have been inadequate for detecting dif-
ferences in secondary outcomes, although it was adequate 
for detecting the required difference in the primary out-
come variable.
Our study has a few limitations. The open-label na-
ture of  this study could lead to some biases with general-
ization of  the results. The sample size was also relatively 
small and further investigation based on a larger number 
of  patients is necessary to corroborate our data. Finally, 
our study duration was relatively short. Indeed, the short 
duration of  most studies and the lack of  follow-up af-
ter treatment cessation leave the question unanswered 
whether antidepressants have long-term beneficial effects 
on FCP symptoms, as well as the optimal treatment du-
ration. Nevertheless, this study is of  value because it is 
the first study examining the efficacy of  amitriptyline on 
patients with FCP with symptoms refractory to a con-
ventional dose of  PPI. We did not encounter major or 
unexpected side effects related to amitriptyline. 
In conclusion, the combination of  low-dose amitrip-
tyline with a standard PPI regimen was more effective 
than a double-dose of  PPIs in patients with FCP refrac-
tory to conventional PPI therapy, without serious adverse 
events. The safety profile and efficacy in the subjects 
using low-dose amitriptyline as well as the significant 
improvement in global symptom scores may justify the 
addition of  amitriptyline for the treatment of  refractory 
FCP.
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